UBS Downgrades Merck (MRK) to Neutral
More News related to MRK
- New Merck Begins Operations
- Trading Outlook for Novavax Inc. Issued by InvestorSoup.com
- Merck and Schering-Plough to Complete Merger Today
- Wells Fargo Downgrades GTx, Inc. (GTXI) to Market Perform; Lack of Near-Term Catalyst Keep Shares Range Bound
- Semi-Annual Changes to the NASDAQ OMX CRD Global Sustainability 50 Index
UBS downgrades Merck (NYSE: MRK) from Buy to Neutral and cuts its price target from $43 to $40.
Merck & Co., Inc. provides various products for human and animal health in the United States and internationally.
Related Categories
DowngradesStocks Mentioned
-0.12Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
